Literature DB >> 7675460

Activation of NF-kappa B/Rel by Tax involves degradation of I kappa B alpha and is blocked by a proteasome inhibitor.

S B Maggirwar1, E Harhaj, S C Sun.   

Abstract

The tax gene product of the human T-cell leukemia virus type I (HTLV-I) induces the nuclear expression and biological function of the NF-kappa B/Rel family of host transcription factors although the underlying mechanism remains unclear. In the present study, we demonstrate that Tax-mediated activation of NF-kappa B/Rel can be inhibited by a proteasome inhibitor, suggesting the involvement of proteolytic reactions in this Tax-specific activation pathway. Transient transfection and reporter gene assays have revealed that Tax overrides the inhibitory function of I kappa B alpha in both F9 embryonal cells and Jurkat T cells. Moreover, Tax-mediated inactivation of I kappa B alpha requires a 16 amino acid sequence element located at the N-terminal region (amino acid 21-36) of I kappa B alpha, which is also required for tumor necrosis factor alpha-induced degradation of this inhibitory protein. We further demonstrate that the proteasome inhibitor also blocks the degradation of I kappa B alpha observed in HTLV-I-infected T cells. Interestingly, inhibition of I kappa B alpha degradation in these cells led to the accumulation of a phosphorylated form of I kappa B alpha. Together, these studies suggest that Tax activation of NF-kappa B/Rel may involve induction of phosphorylation and subsequent proteasome-mediated degradation of the inhibitor I kappa B alpha.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7675460

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  17 in total

Review 1.  Comparative biology of human T-cell lymphotropic virus type 1 (HTLV-1) and HTLV-2.

Authors:  Gerold Feuer; Patrick L Green
Journal:  Oncogene       Date:  2005-09-05       Impact factor: 9.867

2.  Mutational analysis of human T-cell leukemia virus type 2 Tax.

Authors:  T M Ross; A C Minella; Z Y Fang; S M Pettiford; P L Green
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

3.  Characterization of a mutant cell line that does not activate NF-kappaB in response to multiple stimuli.

Authors:  G Courtois; S T Whiteside; C H Sibley; A Israel
Journal:  Mol Cell Biol       Date:  1997-03       Impact factor: 4.272

4.  Distinct domains of IkappaBalpha regulate c-Rel in the cytoplasm and in the nucleus.

Authors:  I Luque; C Gélinas
Journal:  Mol Cell Biol       Date:  1998-03       Impact factor: 4.272

5.  Persistent activation of NF-kappa B/Rel by human T-cell leukemia virus type 1 tax involves degradation of I kappa B beta.

Authors:  L Good; S C Sun
Journal:  J Virol       Date:  1996-05       Impact factor: 5.103

6.  Human T-cell leukemia virus type 2 tax mutants that selectively abrogate NFkappaB or CREB/ATF activation fail to transform primary human T cells.

Authors:  T M Ross; M Narayan; Z Y Fang; A C Minella; P L Green
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

7.  Suppression of lung inflammation in rats by prevention of NF-kappaB activation in the liver.

Authors:  L H Lancaster; J W Christman; T R Blackwell; M A Koay; T S Blackwell
Journal:  Inflammation       Date:  2001-02       Impact factor: 4.092

8.  Activation of the IL-2 gene promoter by HTLV-I tax involves induction of NF-AT complexes bound to the CD28-responsive element.

Authors:  L Good; S B Maggirwar; S C Sun
Journal:  EMBO J       Date:  1996-07-15       Impact factor: 11.598

9.  Interaction of the human T-cell lymphotropic virus type 1 tax transactivator with transcription factor IIA.

Authors:  K E Clemens; G Piras; M F Radonovich; K S Choi; J F Duvall; J DeJong; R Roeder; J N Brady
Journal:  Mol Cell Biol       Date:  1996-09       Impact factor: 4.272

Review 10.  HTLV-1 and apoptosis: role in cellular transformation and recent advances in therapeutic approaches.

Authors:  John M Taylor; Christophe Nicot
Journal:  Apoptosis       Date:  2008-06       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.